Metagenomi Therapeutics (MGX) Total Non-Current Liabilities (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Total Non-Current Liabilities of $57.2 million for Q1 2026, down 31.15% year-over-year from $83.1 million in Q1 2025, and down 5.51% quarter-over-quarter from $60.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Total Non-Current Liabilities for 4 consecutive years, with $57.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 31.15% year-over-year to $57.2 million; the TTM figure through Mar 2026 stood at $57.2 million (down 31.15% YoY), while the FY2025 annual figure was $60.6 million, down 30.98% from the prior year.
- Total Non-Current Liabilities eased to $57.2 million in Q1 2026 per MGX's latest filing, from $60.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $144.6 million in Q4 2023 and bottomed at $57.2 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $92.2 million across 4 years, with a median of $85.4 million in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 39.32% — and 2025, when it tumbled 30.98%.
- Metagenomi Therapeutics' Total Non-Current Liabilities stood at $144.6 million in 2023, then plunged by 39.32% to $87.7 million in 2024, then sank by 30.98% to $60.6 million in 2025, then fell by 5.51% to $57.2 million in 2026.
- Business Quant data shows MGX's Total Non-Current Liabilities at $57.2 million in Q1 2026, $60.6 million in Q4 2025, and $67.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.32 Bn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 59.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.12 Mn |
| Mar 31, 2026 | 57.22 Mn |
| Dec 31, 2025 | 60.55 Mn |
| Sep 30, 2025 | 67.57 Mn |
| Jun 30, 2025 | 74.30 Mn |
| Mar 31, 2025 | 83.10 Mn |
| Dec 31, 2024 | 87.73 Mn |
| Sep 30, 2024 | 99.50 Mn |
| Jun 30, 2024 | 112.68 Mn |
| Mar 31, 2024 | 134.69 Mn |
| Dec 31, 2023 | 144.59 Mn |